{
}
UBS has lowered its price target for Neurocrine Biosciences to $137 from $154 while maintaining a Buy rating, citing a reevaluation of biotech stocks amid market trends. The company, known for its neurological treatments, has seen a 24.6% decline year-to-date but is viewed as undervalued, with strong revenue growth and solid financial health. Recent developments include the appointment of Dr. Sanjay Keswani as Chief Medical Officer and promising results from a study on Ingrezza, which showed significant remission rates for tardive dyskinesia symptoms.
UBS has lowered its price target for Neurocrine Biosciences to $137 while maintaining a Buy rating, citing a favorable risk/reward ratio and the absence of regulatory risks. The company’s lead product, Ingrezza, shows strong sales growth, although challenges in payer coverage may impact demand. Recent clinical trial results indicate promising long-term remission rates for tardive dyskinesia, while leadership changes and cautious revenue estimates reflect the evolving landscape for Neurocrine.
Sanjay Keswani
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers neurocrine biosciences stock target while maintaining buy rating
United States Dollar
Teva Pharmaceutical Industries Ltd
Neurocrine Biosciences, Inc.
USA
Ashwani Verma
Eiry W. Roberts
Sanjay Keswani
Show more
17:47 04.04.2025
ubs lowers neurocrine biosciences price target but maintains buy rating
United States Dollar
Teva Pharmaceutical Industries Ltd
Neurocrine Biosciences, Inc.
USA
Ashwani Verma
Eiry W. Roberts
Sanjay Keswani
Show more
17:29 04.04.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Financial Scams and Security
Retail and Consumer Goods
Market Analysis and Predictions
Banking Regulations
Hedge Funds & Private Equity
CEO Changes
AI Innovations
Supply Chain Management
Industry Mergers & Acquisitions
Global Trade Developments
Workplace Trends
Funding Rounds & Investments
Startups & Entrepreneurship
Cryptocurrency Trends
Government Economic Policies
Countries:
Companies:
JPMorgan Chase & Co.
Barclays PLC
NVIDIA Corporation
Morgan Stanley
Tesla, Inc.
The Goldman Sachs Group, Inc.
Bank of America Corporation
Citigroup Inc.
Wells Fargo & Company
The Charles Schwab Corporation
Capital One Financial Corporation
Apple Inc.
Huawei Technologies CO. Ltd.
Netflix, Inc.
Tesmec S.p.A.
Truist Financial Corp
HSBC Holdings plc
Geode Capital Management LLC
State Street Corporation
Credit Suisse Real Estate Fund Siat
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
British Pound Sterling
Swiss Franc
United Arab Emirates Dirham
Japanese Yen
South Korean Won
Canadian Dollar
Offshore Chinese Yuan
Singapore Dollar
Azerbaijani Manat
New Taiwan Dollar
Saudi Riyal
Vietnamese Đồng
Hong Kong Dollar
Brazilian Real
People: